RxDoctor Payments Data

Jacqueline Carrasco, MD

Ophthalmic Plastic and Reconstructive Surgery · Wynnewood, PANPI 1336148410

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $58,145 of the $63,752 with a category attached, or 91.2%. Amgen accounts for 96.5% of it on its own, with 18 other manufacturers making up the rest.

$63,752in general payments, 2019–2025

Across 175 payments — averaging $364.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$62K
  • AbbVie$421
  • Merz North America, Inc.$274
  • Merz Pharmaceuticals, LLC$231
  • Biotissue Holdings Inc.$229
  • Bausch & Lomb Americas Inc.$183
  • plus $863 from 13 others

What the payments were for

  • Consulting fees$1,3062%
  • Speaking & faculty fees$58,14591%
  • Travel & lodging$2690%
  • Food & beverage$3,9636%
  • Education$510%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$434,005
Medicare patients
594
Services billed
10,889

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast22$26,709
RestasisCyclosporine17$21,709
Cyclosporine29$15,131
TyrvayaVarenicline Tartrate12$7,096
Tobramycin-DexamethasoneTobramycin/Dexamethasone201$6,361
Loteprednol Etabonate27$4,628
Timolol MaleateTimolol Maleate/Pf12$4,083
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha321$4,040
Doxycycline Hyclate69$2,364
ErythromycinErythromycin Base69$1,063
Prednisolone Acetate13$507
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$425
Methylprednisolone91$407
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$171
Cephalexin11$75

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$183$26,70922 claims
AbbVieRestasis$421$21,70917 claims
Oyster Point Pharma, Inc.Tyrvaya$53$7,09612 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$38$4,62827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other ophthalmic plastic and reconstructive surgery in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →